Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2094250 Target Snapshot

Angiotensin II receptor (AT-1) type-1 · PROTEIN FAMILY · Rattus norvegicus

1,046Compounds
134Assays
9Approved Drugs
1,325.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P29089. Use UniProt P29089 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P29089 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Angiotensin II receptor (AT-1) type-1 as ChEMBL target CHEMBL2094250, mapped to UniProt P29089. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Angiotensin II receptor (AT-1) type-1
PROTEIN FAMILY · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL2094250
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P29089
Type-1 angiotensin II receptor B
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Angiotensin II receptor (AT-1) type-1 is the right protein anchor across sources, using UniProt P29089 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelType-1 angiotensin II receptor B
UniProt AccessionP29089
Component TypeProtein
Sequence Length359 aa

Type-1 angiotensin II receptor B

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Angiotensin II receptor (AT-1) type-1, mapped to UniProt P29089. ChEMBL maps the protein component as Type-1 angiotensin II receptor B. Sequence length is 359 aa.

Mapped IDP29089
Review nameAngiotensin II receptor (AT-1) type-1
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

9
Approved
7
Phase II
Assay Mix

Activity Type Distribution

IC501,096.0
KI208.0
KD21.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL313598 10.7 IC50 0.02 Preclinical
CHEMBL87244 10.52 IC50 0.03 Preclinical
CHEMBL90618 10.52 IC50 0.03 Preclinical
CHEMBL315236 10.4 IC50 0.04 Preclinical
CHEMBL89032 10.4 IC50 0.04 Preclinical
CHEMBL431853 10.22 IC50 0.06 Preclinical
CHEMBL312937 10.15 IC50 0.07 Preclinical
CHEMBL314975 10.15 IC50 0.07 Preclinical
CHEMBL338101 10.15 IC50 0.071 Preclinical
CHEMBL84908 10.15 IC50 0.07 Preclinical
Distribution

pChEMBL Value Distribution

29
5.0
21
5.5
52
6.0
102
6.5
141
7.0
170
7.5
225
8.0
173
8.5
111
9.0
95
9.5
pChEMBL
Approved Drugs

Approved Drugs

ANGIOTENSIN II
CHEMBL408403
Approved 2017
EPROSARTAN
CHEMBL813
Approved 1997
IRBESARTAN
CHEMBL1513
Approved 1997
VALSARTAN
CHEMBL1069
Approved 1996
LOSARTAN
CHEMBL191
Approved 1995
LOSARTAN POTASSIUM
CHEMBL995
Approved 1995
SARALASIN
CHEMBL938
Approved 1982
Assay Landscape

Assay Landscape

134
Total Assays
977
Tested Compounds
2
Assay Types
Binding — 81 assays, 977 compounds
BAO Format Assays Compounds Avg pChEMBL
cell membrane format 31 312 8.0
assay format 24 418 8.0
tissue-based format 8 152 8.1
protein format 7 35 8.8
cell-free format 5 6 6.9
microsome format 3 29 7.8
cell-based format 2 4 8.2
organism-based format 1 21 9.3
Functional — 53 assays, 25 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 43 6 7.2
tissue-based format 6 15 7.5
assay format 4 4 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine